Pfizer and BioNTech’s COVID-19 vaccine appeared to only lose a small bit of effectiveness against an engineered virus with three key mutations from the new variant found in South Africa, according to a laboratory study conducted by the drugmaker.
The study indicates the vaccine would likely still be effective in neutralizing a virus with the South African mutations.